Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Amgn source : Www.biospace.com save search
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Published: 2024-04-16 (Crawled : 00:00) - biospace.com/
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
tezspire copd
Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer
Published: 2024-02-15 (Crawled : 14:30) - biospace.com/
SRRK A | $13.94 -0.07% 130K
|
Health Technology
|
| O: 1.61%
H: 0.76%
C: 0.13%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: -0.75%
H: 0.86%
C: 0.41%
rock
Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-04 (Crawled : 22:00) - biospace.com/
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.27%
H: 1.19%
C: 0.55%
conference pipeline
Xencor Reports Third Quarter 2023 Financial Results
Published: 2023-11-07 (Crawled : 00:00) - biospace.com/
XNCR | $18.65 -1.58% 130K
|
Health Technology
|
| O: -0.05%
H: 1.41%
C: 0.82%
OMER | $3.195 -0.47% 61K
|
Health Technology
|
| O: -1.47%
H: 11.57%
C: 5.97%
MOR | $18.0 -0.28% 33K
|
Health Technology
|
| O: 0.36%
H: 0.48%
C: -1.09%
GILD | News | $66.495 0.51% 1.9M
|
Health Technology
|
| O: -0.09%
H: 0.35%
C: -0.57%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.05%
H: 0.38%
C: -0.68%
financial results
AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
Published: 2023-11-02 (Crawled : 14:00) - biospace.com/
BGNE | $130.63 -1.01% 69K
|
Health Technology
|
| O: 0.5%
H: 2.69%
C: -0.09%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.94%
H: 1.82%
C: 1.25%
krystexxa blood show
AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
Published: 2023-11-01 (Crawled : 20:00) - biospace.com/
BGNE | $130.63 -1.01% 69K
|
Health Technology
|
| O: -1.12%
H: 1.26%
C: -1.57%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.22%
H: 1.92%
C: 1.78%
pipeline
A large international study of migraine reveals new biological pathways for treatment
Published: 2023-10-26 (Crawled : 18:00) - biospace.com/
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: -0.24%
H: 0.71%
C: -0.66%
international treatment migraine study
AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS
Published: 2023-10-25 (Crawled : 23:00) - biospace.com/
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: -0.37%
H: 0.58%
C: -1.07%
financial results
AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
Published: 2023-10-16 (Crawled : 18:00) - biospace.com/
XNCR | $18.65 -1.58% 130K
|
Health Technology
|
| O: 0.0%
H: 1.49%
C: 0.53%
BGNE | $130.63 -1.01% 69K
|
Health Technology
|
| O: -3.15%
H: 2.37%
C: 0.45%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.14%
H: 1.16%
C: 0.84%
pipeline research
Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments
Published: 2023-09-27 (Crawled : 08:00) - biospace.com/
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 1.0%
H: 0.69%
C: -1.01%
company life series
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate
Published: 2023-09-18 (Crawled : 14:00) - biospace.com/
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 1.02%
H: 0.7%
C: -0.09%
candidate
Variants in the genome interact with each other and with the environment to affect risk of cardiovascular disease
Published: 2023-09-14 (Crawled : 22:00) - biospace.com/
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.65%
H: 1.64%
C: 1.31%
disease risk cardiovascular
AMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE - September 7, 2023
Published: 2023-09-07 (Crawled : 21:00) - biospace.com/
MS | News 0 d | $91.305 1.16% 1.7M
|
Finance
|
| O: -0.12%
H: 0.0%
C: 0.0%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.61%
H: 1.66%
C: 1.54%
conference global
Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
Published: 2023-08-08 (Crawled : 12:00) - biospace.com/
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 5.42%
H: 2.43%
C: 1.27%
therapeutics financial results
Horizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023
Published: 2023-07-17 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.25%
H: 0.32%
C: -0.19%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: -0.25%
H: 0.76%
C: 0.43%
therapeutics financial results
Adicet Announces Appointment of Katie Peng to the Board of Directors
Published: 2023-07-11 (Crawled : 13:00) - biospace.com/
DNLI | $16.455 -0.87% 120K
|
Health Technology
|
| O: -0.21%
H: 0.07%
C: -0.27%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: -0.4%
H: 0.78%
C: 0.01%
ACET | $1.935 -4.44% 150K
|
Health Technology
|
| O: -0.89%
H: 7.16%
C: -2.09%
FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Published: 2023-06-21 (Crawled : 14:20) - biospace.com/
BGNE | $130.63 -1.01% 69K
|
Health Technology
|
| O: -0.8%
H: 0.36%
C: -2.33%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: -0.18%
H: 0.8%
C: -0.5%
blincyto fda approval treat grants leukemia
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
Published: 2023-05-08 (Crawled : 23:00) - biospace.com/
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
RVMD S | $35.0 -2.32% 190K
|
Health Technology
|
| O: 0.12%
H: 0.37%
C: 0.29%
BCEL P | $0.0761 350K
|
Health Technology
|
| O: 3.0%
H: 1.94%
C: 1.94%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: -0.5%
H: 0.17%
C: -0.31%
update financial results
NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
Published: 2023-05-08 (Crawled : 15:00) - biospace.com/
BGNE | $130.63 -1.01% 69K
|
Health Technology
|
| O: 1.73%
H: 0.92%
C: -0.08%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: -0.5%
H: 0.17%
C: -0.31%
prolia risk
CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research
Published: 2023-05-05 (Crawled : 09:00) - biospace.com/
CRSP M | $56.6 0.78% 340K
|
Health Technology
|
| O: 1.88%
H: 6.97%
C: 3.09%
BIIB | $191.45 0.49% 310K
|
Health Technology
|
| O: 0.08%
H: 1.89%
C: 1.35%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.33%
H: 1.88%
C: 1.66%
west pharmaceuticals research therapy
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.